reports
LivaNova Reports First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis First-quarter U.S. GAAP...
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company’s development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. “I am very pleased to welcome Ahmet to the LivaNova team. At...
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incide...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident that was initially disclosed by the Company on November 20, 2023. The incident resulted in a disruption to portions of the Company’s information technology systems. Promptly after detecting the issue on November 19, 2023, LivaNova began an investigation with assistance from external cybersecurity experts and coordinated with law enforcement. The Com...
LivaNova to Announce First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2024 results prior to the call. A live audiocast will be accessible at . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial (if dialing from within the U.S.) or (if dialing from outside the U.S.). The...
LivaNova Announces a Positive Predictive Outcome of Trial Success in i...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its , has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated. This means there is a greater than 97.5% probability that the OSPREY trial will successfully meet its primary endpoint. OSPREY is a prospective, multi-center, randomized controlled open-label trial demonstrating the safety and effectiveness of the aura6000™ Hypoglossal Nerve Stimulator System versus a no stimulation control in subjects with moderate to severe obstructive sleep ...
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 (the “notes”) to be issued in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In addition, LivaNova has granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes ...
LivaNova Announces Proposed Private Offering of $300 Million of Conver...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors. LivaNova also intends to grant to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and in...
LivaNova to Present at the Barclays Global Healthcare Conference
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 10:45 a.m. Eastern Time on Tuesday, March 12. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on ...
- Dave Nicoski
- Ross LaDuke
LIVN LIVANOVA PLC
INT WORLD FUEL SERVICES CORPORATION
HBI HANESBRANDS INC.
GPC GENUINE PARTS COMPANY
DORM DORMAN PRODUCTS INC.
DG DOLLAR GENERAL CORPORATION
BBW BUILD-A-BEAR WORKSHOP
BBY BALFOUR BEATTY PLC
LOK LOK 'N STORE GROUP PLC
OXM OXFORD INDUSTRIES INC.
UA UNDER ARMOUR INC. CLASS C
CLF CLEVELAND-CLIFFS INC
EYE NATIONAL VISION HOLDINGS
RCUS ARCUS BIOSCIENCES
RVLV REVOLVE GROUP
STOK STOKE THERAPEUTICS
RPRX ROYALTY PHARMA PLC CLASS A
LPI LAREDO PETROLEUM INC.
HPK HIGHPEAK ENERGY INC (A)
MRVI MARAVAI LIFESCIENCES HOLDINGS
ATNM ACTINIUM PHARMACEUTICALS INC
LMND LEMONADE INC
ACVA ACV AUCTIONS INC
LYEL LYELL IMMUNOPHARMA INC
AMLX AMYLYX PHARMACEUTICALS INC
SCLX SCILEX HOLDING COMPANY
HIPO HIPPO HLDGS INC
LivaNova Reports Fourth-Quarter and Full-Year 2023 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024. Financial Summary and Highlights1 Fourth-quarter revenue of $310.1 million increased 12.8 percent on a reported basis and 11.9 percent on a constant-currency basis, as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share was $0.30 and adjusted diluted earnings per share was $0.87 Full-year 2023 revenue of $1.15 billion increased 12.9 percent on a ...
LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of Directors, effective March 1, 2024. Makatsaria most recently served as Company Group Chairman at Johnson & Johnson MedTech, leading its global Ethicon surgery business. “Vlad is a respected leader in the medical device industry with a proven reputation for delivering results, driving innovation and building great teams,” said Bill Kozy, LivaNova Board ...
LivaNova to Wind Down Advanced Circulatory Support Business Unit
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it will commence immediately with an orderly wind down of the Advanced Circulatory Support (ACS) Business Unit to increase the Company’s strategic focus on its core Cardiopulmonary (CP) and Neuromodulation Business Units. ACS generated approximately 4% of net revenue for the nine months ended September 30, 2023. The wind down is anticipated to be complete by the end of 2024. The Company will retain all ACS standalone cannulae products and related accessories, including Pro...
LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2023 results prior to the call. A live audiocast will be accessible at . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial (if dialing from within the U.S.) or (if...
LivaNova to Present at the Piper Sandler Healthcare Conference
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at the Piper Sandler Healthcare Conference in New York. The presentation will take place at 8:30 a.m. Eastern Time on Wednesday, November 29. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay...
LivaNova Reports Third-Quarter 2023 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2023 and raised full-year 2023 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights1 Third-quarter revenue of $286.1 million increased 13.3% on a reported basis and increased 12.1% on a constant-currency basis, as compared to the prior-year period Third-quarter U.S. GAAP diluted loss per share was $0.14 and adjusted diluted earnings per share was $0.73 Received U.S. FDA 510(k) clearance an...
LivaNova to Present at the Stifel and Wolfe Healthcare Conferences
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present a general business update during fireside chats at two healthcare conferences in New York in November: Stifel Healthcare Conference 2023 on Tuesday, November 14 from 9:10 - 9:40 a.m. ET 5th Annual Wolfe Research Healthcare Conference on Wednesday, November 15 from 11 - 11:40 a.m. ET The Stifel and Wolfe fireside chats will stream live with recordings available afterward. To access event ...
LivaNova Board Appoints J. Christopher Barry as New Director
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today. Barry will serve on the Audit and Compliance Committee. Andrea Saia, who has served as a Director since 2016, will retire from the LivaNova Board on December 31, 2023. “The LivaNova Board of Directors is pleased to welcome Chris Barry,” said Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova. “Chris has spent his career in the medical technology industry, and we look forward t...
LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retir...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Marco Dolci intends to retire as President of the Cardiopulmonary (CP) Business Unit (BU) by December 31, 2023. Dolci will continue in his role and support the transition of responsibilities through the end of the year. Franco Poletti will serve as Interim General Manager of CP to support the transition efforts, in addition to his current role as Vice President of CP for Europe, effective immediately. LivaNova will retain a leading international executive search firm to assi...
LivaNova to Announce Third-Quarter 2023 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2023 results on Wednesday, November 1, 2023 at 12 p.m. London time (8 a.m. Eastern Time). The Company will release its third-quarter 2023 results prior to the call. A live audiocast will be accessible at . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial (if dialing from within the U.S.) or (if dialing from outside the U.S....
LivaNova dévoile son moniteur de sang en ligne Essenz, qui dispose de ...
LONDRES--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq : LIVN), un chef de file des technologies médicales, annonce aujourd’hui avoir reçu l’approbation 510(k) de la Food and Drug Administration (FDA) des États-Unis et le marquage CE pour son moniteur de sang en ligne (ILBM) Essenz™, qui fournit une mesure précise et continue des paramètres sanguins essentiels aux perfusionnistes tout au long d'un pontage cardiopulmonaire. L’ILBM est intégré à la plateforme de pontage cardiopulmonaire de prochaine génération de LivaNova, le système de perfusion Essenz™, qui permet aux perfusionnistes d’accéder et de ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.